Obesity treatment with a progressive clinical tri-therapy combining sibutramine and a supervised diet--exercise intervention

Int J Obes Relat Metab Disord. 2001 Aug;25(8):1144-53. doi: 10.1038/sj.ijo.0801677.

Abstract

Objective: : Sibutramine favors a negative energy balance and also has the potential to increase heart rate and blood pressure. We investigated if a progressive supervised sibutramine--diet--exercise clinical intervention could increase the body weight loss previously reported while minimizing the potential cardiostimulatory effects of this drug.

Design and subjects: : The tri-therapy intervention was divided into two phases of 6 weeks each in which sibutramine (10 mg) was taken once daily by eight obese men (body mass index (BMI) between 30 and 40 kg/m(2)). Part A consisted of a dietary follow-up with an energy restriction, whereas in part B an aerobic exercise program combined with a low-fat diet was introduced. Systolic (SBP) and diastolic (DBP) blood pressure, resting heart rate (RHR) and body weight were measured every 2 weeks while body density, resting metabolic rate (RMR) and respiratory quotient (RQ) were determined before and after the intervention.

Results: : This clinical intervention produced a substantial body weight loss (-10.7 kg, P<0.01) which was about twice as much as other 12-week studies. In part A, both RHR (+4 beats/min) and DBP (+5 mmHg, P<0.01) were increased. However, after part B, RHR (-8 beats/min, P=0.02) and DBP (-3 mmHg, P<0.01) were significantly decreased. RMR was decreased at the end of the program but this effect did not persist after adjustments for fat-free mass. RQ was also reduced (-0.05, P<0.01) following the clinical tri-therapy.

Conclusion: : In conclusion, these observations suggest that this clinical tri-therapy favored a satisfactory benefit--risk profile since it enhanced weight loss without inducing increases in heart rate and blood pressure or detrimental changes in RMR and substrate oxidation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Basal Metabolism / drug effects
  • Blood Pressure / drug effects
  • Body Weight / drug effects
  • Cyclobutanes / adverse effects*
  • Cyclobutanes / therapeutic use*
  • Diet, Reducing*
  • Energy Metabolism
  • Exercise*
  • Heart Rate / drug effects
  • Humans
  • Male
  • Obesity / therapy*
  • Oxygen Consumption
  • Risk Assessment

Substances

  • Cyclobutanes
  • sibutramine